Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 5/20 | 0.44 |
| ▸ | MME | P08473 | 5/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.44 |
| ▸ | CPA1 | P15085 | 3/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | IL2 | P60568 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325154 | 1.00 | FPR2 (0.54) | FPR2CYP1A2CYP2D6ACEMME | |
| Hydrochloric Acid SCHEMBL2521612 | 0.98 | FPR2 (0.52) | FPR2CYP1A2CYP2D6ACEMME | |
| SCHEMBL24311640 | 0.86 | CYP1A2 (0.44) | FPR2CYP1A2CYP2D6ALBIL2 | |
| SCHEMBL24311576 | 0.86 | CYP1A2 (0.44) | FPR2CYP1A2CYP2D6ALBIL2 | |
| SCHEMBL8717678 | 0.84 | FPR2 (0.46) | FPR2CYP1A2CYP2D6APEX1PMP22 | |
| SCHEMBL14037245 | 0.84 | FPR2 (0.46) | FPR2CYP1A2CYP2D6APEX1PMP22 | |
| SCHEMBL161943 | 0.84 | FOLH1 (0.60) | ACEMMEACE2CPA1FOLH1 | |
| SCHEMBL8693619 | 0.84 | FPR2 (0.55) | FPR2CYP1A2CYP2D6ACEMME | |
| SCHEMBL8745399 | 0.84 | FPR2 (0.55) | FPR2CYP1A2CYP2D6ACEMME | |
| SCHEMBL160418 | 0.84 | FOLH1 (0.60) | ACEMMEACE2CPA1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028793-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2026-05-12 | — | — | CN | claimed |
| CN-118265452-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2024-06-28 | — | — | CN | claimed |
| CN-115697056-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115697055-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115666239-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115666240-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115666241-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115666238-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2023-01-31 | — | — | CN | claimed |
| CN-122028793-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-118265452-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20050159346-A1 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY | 2005-07-21 | — | — | US | disclosed |
| WO-2005034982-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FPR2 1502/4885CYP1A2 4845/4885CYP2D6 4576/4885 |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | VIP, IAPP, NGLY1 | FPR2 1498/4885CYP1A2 4882/4885CYP2D6 4842/4885 |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | VIP, IAPP, NGLY1 | FPR2 1498/4885CYP1A2 4882/4885CYP2D6 4842/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | FPR2 541/4885CYP1A2 4648/4885CYP2D6 2906/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | FPR2 1502/4885CYP1A2 4845/4885CYP2D6 4576/4885 |
| US-20050159346-A1 | Cyclic peptide antitumor agents | VIP, IAPP, NGLY1 | FPR2 1498/4885CYP1A2 4882/4885CYP2D6 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.